Reddit Posts
NRx Pharmaceuticals (NRXP) - Two September Catalysts Upon Us
$NRXP - Vanguard & BlackRock Accumulating Heavily Ahead of Key 2026 Commercial Launch 🚀
$NXRP Vanguard & BlackRock Accumulating Heavily Ahead of Key 2026 Commercial Launch 🚀
The important "rest of the story" you need to know regarding NRx Pharmaceuticals (NRXP) and the anticipated upcoming ANDA approval for no-preservative IV ketamine
NRx Pharmaceuticals (NRXP) - Awaiting ANDA (generic drug) approval for no-preservative Intravenous (IV) ketamine for analgesia (pain control) and anesthesia ... which will happen in the near term.
NRx Pharmaceuticals (NRXP) - Imminent Catalyst - 8-K dropped today (follow-up to yesterday's post - I encourage you to check it out). The stock is up nicely this morning, as a result! One of my favorite companies to hold. This company is a winner ... now ... and longer term.
NRX Pharmaceuticals (NRXP) - Imminent Catalyst and other statuses! This company is on the move and gaining traction. Price targets are multiples of the current share price.
$NRXP raised capital at $3.50/share, creating a clear reference level for traders watching support, volume, and potential post-offering recovery action.
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
$NRXP - The validated technology is being deployed across the Hope Therapeutics interventional psychiatry network as a patient-facing self-monitoring and safety-net tool.
Bullish on $NRXP 🚨 ✅ Commercial ketamine manufacturing initiated ✅ FDA feedback reportedly only “minor” admin items remaining ✅ Positioned for potential approval this summer ✅ Addressing ongoing ketamine shortages Undervalued mental health biotech with real momentum building. 💊📈
Thoughts on NRXP after Trump’s psychedelic/FDA executive order?
$NRXP News Update :NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications
$NRXP - Hope Therapeutics (subsidiary of NRx Pharmaceuticals, Nasdaq: NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network.
$NRXP - NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA Center for Drug Evaluation and Research.
$NRXP - The January 26, 2026 deadline will also apply in determining whether a stockholder proposal or nomination is timely for purposes of exercising discretionary voting authority under Rule 14a-4(c) of the Exchange Act.
How to check if the company you like is going bankrupt! (NXXT, BURU, etc)
NRXP: FDA Decision Dec 31 + 38% Short Spike = Potential Binary Catalyst. Here's the Due Diligence.
Why Bristol Myers Squibb Should Buy NRXP
NRX-101 + Transcranial Magnetic Stimulation (TMS) for NRx Pharmaceuticals (NRXP)
$NRXP HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health
Earnings Week Breakdown: What’s Coming Friday Through Tuesday (NXXT, NRXP, CAN and more)
$NRXP HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health
NRX Pharmaceuticals, Inc. (ticker: NRXP)
$NRXP - NRx Pharmaceuticals is making NRX-100 available on an expanded access basis upon physician request for patients with serious or life-threatening suicidal depression despite treatment with currently available therapy.
$NRXP - Dura Medical, together with pending acquisitions of Neurospa TMS and Cohen & Associates, to provide contiguous coverage at more than 8 locations along Florida’s West Coast, with planned coverage throughout the Florida Peninsula
NRx Pharmaceuticals (NRXP) -- Is anyone seeing a pattern here? Third analyst enters, and now with a $40 price target ... AND ... NRx's HOPE Therapeutics closes on Dura Medical clinic acquisition in Florida! This journey is quickly unfolding per plan. Comprehensive post link below. A WINNER HERE!
NRx Pharmaceuticals (NRXP) -- Recently posted the newly updated price targets of $25 and $34. Another significant PR today - they keep coming! Potential to make an excellent return on a current $2.60 share price. Consider making a DECISION TO BE A PART OF this incredible mission; IT IS HAPPENING!
I accidentally bought nrxp stock for 2.32, is it alright?
My Top 5 Watchlist: Price Targets and Triggers
Top 5 Mixed Cap Blend (For Diversified Degens)
Top 5 Friday Radar-Catalysts And Clear Levels
NRXP – Why NRX-100 Might Be the Most Asymmetric Play in Biotech Right Now
Today, price target for NRx Pharmaceuticals (NRXP) upgraded once again by BTIG, which shows even greater confidence in probability of success. The outstanding list of Q2 accomplishments and status with the FDA are obviously very compelling.
NRx Pharmaceuticals (NRxP) - After very recent earnings call, probability of success and price target raised -- background included in this post. The time is drawing near!
Top 5 For Traders: Breakouts, Rebounds, And A Round-Number Flip
Reddit Ticker Mentions - AUG.20.2025 - $PLTR, $INTC, $NVDA, $UNH, $OPEN, $WWR, $AMD, $ADD, $DFLI, $NRXP
Reddit Ticker Mentions - AUG.20.2025 - $PLTR, $INTC, $NVDA, $UNH, $OPEN, $WWR, $AMD, $ADD, $DFLI, $NRXP
NRx Pharmaceuticals (NRXP) has made outstanding progress in Q2 2025 (results below) and is setting up for an FDA approval decision in the near term
Reddit Ticker Mentions - AUG.18.2025 - $UNH, $ASTS, $RDDT, $NVDA, $RKLB, $PLTR, $BYD, $NBIS, $ONDS, $NRXP
Reddit Ticker Mentions - AUG.18.2025 - $UNH, $ASTS, $RDDT, $NVDA, $RKLB, $PLTR, $BYD, $NBIS, $ONDS, $NRXP
NRx Pharmaceuticals (NRxP) -- This one is LIVE! Analysts just upgraded their targets to $21 and $31 based on Fast Track granted by FDA this week. Has two drugs that address the national crisis of suicidal ideation in depression, including bipolar depression. Aiming for PDUFA/approval in 2025.
$NRXP - announces that it will release its second quarter 2025 financial results after the market closes on Thursday, August 14, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call at 4:30pm ET the same day. h
$NRXP - Cohen is one of the premier Interventional Psychiatry clinics in the region. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Spravato, Transcranial Magnetic Stimulation ("TMS") as well as medication management.
I posted about SPRO before it ran. NRXP is next. Up twenty five percent already since I posted with June 30 PDUFA coming
I called SPRO before it ran. Now NRXP is next. Up 25% already since I posted with June 30 PDUFA coming
$NRXP - Pharma stock on the cusp of FDA approval
What is going on with NRXP stock ?
NRXP – Tiny Biotech Just Scored $10.3M to Launch National Ketamine/TMS Mental Health Chain – Starting With VA-Approved Clinics
$NRXP - The terms of the Series A Preferred will be defined in a Certificate of Designation to be filed with the State of Delaware, and expected to provide for, among other things, a dividend based on current market conditions and the right to appoint a director to HOPE's Board.
$NRXP - Delivers a full range of precision psychiatry services for severe depression and PTSD, including Ketamine Therapy and Transcranial Magnetic Stimulation (TMS), to veteran and civilian patients
$NRXP - The Term Sheet, which is non-binding and subject to the execution of a definitive Stock Purchase Agreement, contemplates an investment of $2.5 million to purchase Series A Convertible Preferred Stock (the "Series A Preferred") at a $50 million pre-money valuation.
$NRXP HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: $NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE
$NRXP - The Term Sheet, which is non-binding and subject to the execution of a definitive Stock Purchase Agreement, contemplates an investment of $2.5 million to purchase Series A Convertible Preferred Stock (the "Series A Preferred") at a $50 million pre-money valuation.
FULL Nasdaq Article by Ari Zoldan: How Three Companies Are Taking Aim at Alleged Naked Short Sellers - 28 Nov 2023 - (immortalized in photos + links)
NRXP FDA provided Written Responses on January 10 th. As previously announced in October 2022 , an updated NRX-101 module 3 was submitted to add the intended commercial manufacturer to the IND. With FDA's written response, it appears that NRx Pharmaceuticals has reached alignment with the FDA
BREZ has the best risk/reward for SPACs since CCIV in 2021 at $12, low float with huge call OI for May + gamma squeeze potential
It’s criminal for Fauci to delay approval of Zyesami from $NRXP and $RLFTF. Now Ted Cruz is all over it to make sure it happens…link below. This needs to be all over Fox News, joe Rogan, etc ASAP
Senator Ted Cruz pressing Fauci for why RLFTF (relief) and NRXP’s Zyesami hasn’t gotten eua yet and is saving lives from covid!!!!. Guys you need to see this. This needs fo be blasted ALL over the news. This is criminal what the FDA does. PLEASE READ the link below. CONGRESS is all over this!!!!
NRXP, 673K shares bought by someone, Zyesmi works for COVID patients
NRXP Short Volume 55%, Is it setting up for a squeeze?
NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron Surge
NRx Pharmaceuticals (NRXP) CEO to Provide Business Update on January 10th
Relief Therapeutics (RLF.SW, RLFTF) Is flying again today, NRXP will follow too.
Proud holding Relief Therapeutics (RLF.SW, RLFTF) & NRXP! https://miamicourant.com/stories/617928153-op-ed-the-emergency-use-law-should-be-used-for-emergencies-like-now
Relief Therapeutics (RLF.SW, RLFTF) flying today 46% and more to come🤞, NRXP just released a PR for a new EUA submission. With this one approved both of them will have a huge run!
NRXP Stock Rumbles On Request For Therapy Designation.
NRXP NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil)
NRXP 0 shares available, has filled gap back down after its covid variant vaccine PR. Said they will be testing on new variant
$NRXP Zyesemi and BriLife is the Covid19 game changer. Don’t miss on this one (like I almost missed LGVN).
Play for tomorrow is BMTX and NRXP 🚀🚀🎉🎉🎰🎰 Don’t miss this one out!!
NRXP- held up nicely today as still 23% up from Friday close
NRXP Covid Vaccine don't sleep on it, I see it squeezing back to high 9s 😉💥
CONFUSED! NRXP Study looks towards EUA but price still falling? Any Medical People know why?
NRXP Stock: Aviptadil Effective In Increasing COVID Recovery Odds & Surv...
$NRXP is the play, 23M float, 4.5% short of float (Finviz).
Mentions
They are still there. The rising oil price and interest rate is causing pressure on the share price of many companies. The FDA set a date of Nov 10 for the KETAFREE ANDA PDUFA decision. The FDA changing their initial Major Amendment to now Minor Amendment and not making the PDUFA/approval decision date Oct 10 (60 days away like a normal Type 1 CRL) shows whoever is handling this process at the FDA is really confused. The NRX-100 filing better happen by the end of this month as I believe the CEO alluded it would on the Aug 10 call. I wrote him and said we need to see it happen and I hoped it is not being delayed due to waiting to see if the FDA accepts the attestation they sent in for KETAFREE. Bottom line, it is an issue of timing. The whole market could fall soon but I will use any further notable drop in NRXP share price to average down. That’s my plan.
CYCU, NRXP, AIXI (microfloat)
I agree. I have posted several times on NRXP, last year and including recently. My speculation: Near-term $10 to $12 with ANDA approval and NRX-100 filing this month. Depending on FDA timeline for NRX-100 approval, April/May 2027 likely, then $20 to $25. By fall to eoy 2027 (big revenues and NRX-101 NDA filed and priority review, $35+.
Yea, yet another very misguided post regarding NRXP 1.) To achiece high market penetration with KETAFREE, they'll have to sell it at a reduced margin. Also, they have explicitly stated that KETAFREE revenue is ALREADY included in the cash runway projection, which is only through Q1 2027. That means even with approval and perfect execution, they will have to either use the ATM or take on debt no later than Q2 2027. 2.) Let us not forget the PDUFA date NRX provided to investors for NRX 100 was "by 12/31/2025." They were to have filed the NDA well in advance of that. Additionally, on the Q3 2025 call which took place in November of 2025, NRX stated, verbatim, "the NDA will be filed in the coming weeks." They also stated that they "are still seeking a CNPV for it." They will never, and I do mean never, receive a CNPV for it. 3.) The citizens petition will also never be granted for 100 because it would effectively fly right in the face of the CNPV approval should they get it. You would cut the market from multiple suppliers to one, for a drug that is already on a shortage. Never going to happen. 4.) The price targets that are set by ALL of the covering analysts, with the exception of the recent revision by BTIG, are, how can I put this, flat out ludacris. Every single company that has an analyst issue a rating and PT is involved in providing other services to NRX via underwriting, acquisitions, or financing. That means they have a conflict of interest. They are nothing more than cheerleaders/salesman of the stock because it is in their own best interest for it to perform. Just look up the issuing analysts success rates and average rates of return. If they are even close to right on NRX, it would materially impact all of their average rates of return. So, again, never going to happen. The absolute best case bull scenario which includes perfect execution of sales, NRX 100 NDA filing, and NRX 101 progression is to HOPEFULLY see $10 12 months from now.
NRXP. The world goes to sh\*t. Treatment resistant depression goes up.
Ran the tickers people named in this thread against Form 4 filings since June. Most have nothing. Two are worth separating, because they look identical in a scanner and are not the same thing at all. PRQR is the clean one. Five open market buys since 30 June from two insiders, both directors, both starting from zero: 6/30 Filius, 150,000 at $1.54 7/8 de Boer (CEO), 150,000 at $1.59 7/13 de Boer, 150,000 at $1.74 7/21 Filius, 150,000 at $1.7195 8/3 de Boer, 200,000 at $1.7698 de Boer is at 500,000 shares, Filius at 300,000, about $1.34M between them. All code P. They paid up on every purchase instead of averaging down. OTLK reads the same way in a feed and is not. Four filings dated 8/14, all code P: CEO Jahr 151,515, CFO Kenyon 101,010, Sukhtian 2,525,252. But footnote F1 says those shares were acquired "in the Issuer's underwritten public offering" with accompanying warrants attached, expiring in 2031. That is participating in a financing, not buying from the market. The Sukhtian block is also held through GMS Ventures rather than personally. OCGN has one code P, the CFO at 21,000 on 6/17 at $1.23. NRXP, KPTI and AUTL have no code P filings in that window at all. Not telling anyone what to do with that. Just worth knowing the transaction code is identical on PRQR and OTLK, and the footnote is the only thing that separates them.
I have NRXP on my watchlist
If NRXP gets the fda approval, it would be a huge boost - the question is when will they get the green light.
NRXP....Alot of potential and a really potential catalyst in the near future...does have ATM, so potential dilution to raise capital could happen at some point. https://www.tipranks.com/news/company-announcements/nrx-pharmaceuticals-earnings-call-signals-cautious-momentum?utm_source=robinhood.com&utm_medium=referral
Quick heads up — NXRP isn't a ticker that comes up; I think you mean NRXP (NRx Pharmaceuticals). Assuming that's the one: Pulled their latest 10-Q (quarter ended March 31). It's a clinical-stage biopharma, so it looks like most early-stage drug names — thin. About $6.7M in cash, \~$1M of revenue in the quarter, and a reported net loss around $1.4M. The number that matters more here is the cash burn: they actually used about $4.3M running the business that quarter, so the small net loss is flattered by some non-cash items. At that burn against \~$6.7M of cash, runway is short — a raise (and more dilution) looks likely before too long. Equity is negative too, with liabilities around $26M. Share count is still smallish at \~36M. Not advice, just what the filing shows.
Following [$NRXP](https://aimytrade.io/ticker/nrxp?utm_source=reddit&utm_medium=comment&utm_campaign=RobinHoodPennyStocks&utm_term=NRXP&utm_content=template_1780590525426_me75xi) for a while now. I look at where the calculated levels sit before forming a view. Still deciding.
NRXP GOING TO 5?!??!! Graduating soon?!?!’
Don’t forget about NRXP yeah
NRXP for me NRXP is attractive because it combines a low market capitalization with multiple FDA catalysts. NRX-100 (preservative-free ketamine) targets depression and suicidality, has Fast Track designation, and appears to be progressing through the FDA process with encouraging regulatory feedback. If approved, it could address a significant mental health treatment market while providing NRx with a potentially differentiated ketamine product.
NRXP looking good in the after hours!!
NRXP looking good at overnight market 👀
FDA submission soon - you won’t want to miss NRXP! Let’s go to 6 soon.
I beg you guys.. take a look at NRXP.. it should be good for you
NRXP algorithm triggered. Time for a bounce!!
I called NRXP at 3.4, 3.6 and now 3.95. Next target I guessing it would be 5. Come on you NRXP peeps!
NRXP to 4 is within possibility!! Military stock + biomed?!? NRx Pharmaceuticals reported significant progress in the first quarter of 2026, including anticipated FDA approval for its preservative-free ketamine product, KETAFREE, expected by Q3 2026 amid positive preliminary evaluations from the FDA. The company has begun commercial manufacturing at a rate of one million doses per month and secured favorable FDA feedback during a Type C meeting. The launch of NRX-101, an adjunct therapy for Transcranial Magnetic Stimulation (TMS), is also on track, supported by non-dilutive federal funding. Key appointments, such as Prof. Joshua Brown as Chief Medical Innovation Officer, and the establishment of NRx Defense Systems, Inc. for military applications further enhance NRx's capabilities.
Analysts estimate $NRX Pharmaceuticals (NRXP.US)$ to post revenue of USD25.57M for 2026Q1, EPS is estimated to be USD0.288. The accounting standard used for the above data is US-GAAP.
Don’t sleep on NRXP…. I sense some insider buys
WILMINGTON, Del., May 14, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its first quarter 2026 financial results before the market opens on Monday, May 18, 2026 via press release, which will be available on the Company's website at . The Company will host a conference call at 8:00am ET the same day.
$NRXP Ketamine FDA approval possible this summer
How long have you been in NRXP? Not many people know or even follow it, at least from what I have seen.
NRXP is a good stock to get into it aligns perfectly for this
Here is a timeline of the key events: * **March 17, 2026:** The FDA's Office of Generic Drugs issued a favorable **bioequivalence determination** for NRx's ketamine product. * **April 16, 2026:** The White House issued an **Executive Order** directing the expedited approval of drugs to treat severe depression, suicidality, and PTSD. This executive order was specifically cited by the company as a factor in its discussions with the FDA. * **April 21, 2026 (After Market Close):** NRx announced it received a positive **Discipline Review Letter** from the FDA's Office of Generic Drugs. The letter covers the drug's quality, including manufacturing and microbiology, and requests only **"minor" administrative changes**. * The company also met with FDA leadership, who expressed **support for approval within the current review cycle**, targeting a final approval decision in **Summer 2026**. * The U.S. Department of Veterans Affairs has identified ketamine as **"medically necessary"** for treating suicidality and treatment-resistant depression * FORECAST * the stock has responded positively to this news. * **Performance:** Shares posted a **17% return over the last week** following the regulatory updates. * **Market Data:** As of April 22, 2026, NRXP has a market capitalization of approximately **$97.5 million**. Analysts forecast **67% revenue growth for fiscal 2026**, with expectations for the company to achieve profitability this year after recent losses
What happen to NRXP? Why it went up by 15%?!
NRXP with both defence and biomed catalysts?!
NRXP LETS GOOOO NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces the appointment of Glenn Tyson as the company's first Chief Commercial Officer. As NRx looks forward to the anticipated approval of its Abbreviated New Drug Application for their preservative-free ketamine product, it looks to build its commercial capabilities and prepare for a successful launch.
NRXP!! NRX Pharmaceuticals (Nasdaq:Nrxp) Announces Appointment of Glenn Tyson as the Company’s First Chief Commercial Officer Commercialisation will make this company go booooooommmm
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year -HUBC: $920k cash vs $129.5m in current liabilities
For a dead cat bounce or short term play, you guys can consider LNKS, its making moves in the overnight market. Longer term u can consider NRXP
NRXP still moving strong
NRXP is slowly slowly heading upwards. Potential re rating soon!!
NRXP CGTX!!! Lets go FEMY BOIS
is anyone in NRXP? [https://www.tradingview.com/news/reuters.com,2026:newsml\_L8N40C1JP:0-nrx-pharmaceuticals-inc-reports-results-for-the-quarter-ended-december-31-earnings-summary/](https://www.tradingview.com/news/reuters.com,2026:newsml_L8N40C1JP:0-nrx-pharmaceuticals-inc-reports-results-for-the-quarter-ended-december-31-earnings-summary/)
BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $25 price target.
Yes! I'm invested in a few other cancer stocks that could go high based on current share price - MAIA, AUTL, CHRS. But IOVA is a strong contender. Outside of that I'd bet DVLT, NRXP and FEMY (heavy on this choice because they have so much going for them).
NRXP news today is legit. Its a speculative 2-4 year play.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
Y'all are still shilling this one eh? - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
Waiting for MIST, NRXP, and AUID for news. One of these days.
NRXP watch for approval timeline
I bought $NRXP at the peak thinking the Jan 26 deadline meant something bullish would happen. Turns out it's just SEC compliance theater. At least I mapped the damage here: [$NRXP](https://aimytrade.io/s/NRXP?utm_source=reddit&utm_medium=comment&utm_campaign=RobinHoodPennyStocks&utm_term=NRXP&utm_content=variant_1771448538690_m30cf6)
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
NRXP has to pull out of the hole it got dropped in. It was holding solid over $2.
NRXP and CABA looking good rn!!
How t f are you making money with NRXP? it's been a bloodbath from the beginning..I seriously have the CEO, but can't sell yet, too far down
I've followed NRXP for a while. No way you 2.5 call on that is in the money like youre showing. Fake.
*SCAM ALERT* The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert • NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution • BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution • NRXP: *$7m cash and *$30.6 million debt/payables due this year and no way to pay beyond dilution • OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. • MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. *NRXP recently diluted investors to pay off its debt balance. A very large current liabilities balance still remains.
Here are some examples of commonly posted/pumped stocks will horrendous balance sheets. I anticipate every single one of these companies will massively dilute shareholders within the next 6-12 months in an attempt to stay afloat. I doubt it'll work. NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution NRXP: *$7m cash and *$30.6 million debt/payables due this year and no way to pay beyond dilution OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. *NRXP recently diluted investors to pay off its debt balance. A very large current liabilities balance still remains.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date
BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $25 price target.
LMAO more dilutive debt. Ontop of: The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert • NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution • BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution • NRXP: *$7m cash and *$30.6 million debt/payables due this year and no way to pay beyond dilution • OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. • MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. *NRXP recently diluted investors to pay off its debt balance. A very large current liabilities balance still remains.
NRXP is bottoming on 36x their 90 day average volume on news that they’re trying to accelerate FDA approval 👀
Hopefully I can nab some at open NRXP - submitted 70,000 real world patient reviews datset with their already submitted fda application
NRXP! Mark my words it will be a 10 bagger in 2 years time
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill.